Kernaussagen
- 1Act the same day: count remaining doses, call several pharmacies, and contact your prescriber with your run-out date.
- 2Most shortages affect a specific presentation, not the molecule — the pharmacist can often substitute without changing your treatment.
- 3Therapeutic alternatives within the same class need prescriber approval, not just pharmacist substitution.
- 4Build resilience before the next shortage: refill early, keep a two-week buffer, and know your medicine's salt name.
Auf dieser Seite
1The first 24 hours
Act on the same day you discover the problem. Options narrow considerably as your remaining supply shrinks.
- 1Count exactly how many doses you have left and write the run-out date down.
- 2Ask your pharmacy to check its wholesaler network and other branches, not just local stock.
- 3Call three or four other pharmacies in your area — stock is rarely evenly distributed.
- 4Check your national regulator's shortage database to see whether this is a formal supply disruption.
- 5Contact your prescriber with the run-out date and ask about an alternative product or strength.
- 6If the medicine is critical, say the word 'critical' explicitly so it is triaged accordingly.
2Substitutions that are usually acceptable
Many shortages affect a specific presentation rather than the molecule itself. A pharmacist can often solve the problem without changing your treatment at all — but these decisions belong to the pharmacist or prescriber, not to you.
- Different manufacturer, same salt and strength — usually straightforward.
- Different strength with an adjusted count, for example two 5 mg instead of one 10 mg, where the formulation permits.
- Different pack format, such as vial instead of prefilled syringe.
- Different but equivalent formulation, for instance tablet instead of capsule.
- A therapeutic alternative within the same class, which does require prescriber approval.
3Reducing your exposure to the next shortage
Shortages are driven by concentrated manufacturing, single-source ingredients and thin margins on older generics. They are unlikely to disappear, so resilience is worth building.
- Refill a week early rather than on the last day.
- Maintain a two-week buffer where expiry and storage allow.
- Know the salt name, not just the brand, so you can search alternatives yourself.
- Ask whether your medicine has multiple manufacturers or only one.
- Keep a written list of nearby pharmacies with direct phone numbers.
Was der Jivan-Datensatz zeigt
- 59×
- durchschnittliche Preislücke
- 84%
- der Anker übersteigt 10×
- 344×
- größte dokumentierte Lücke
Across our full referenced dataset, 476 referenced molecules average a 59× price gap, 84% of them are at least 10× cheaper in India, and the widest documented comparison is Colchicine at 344×. Across the full referenced dataset the gap is systematic rather than anecdotal: 84% of anchored molecules are at least 10× cheaper, with a 59× average ratio — a market-structure effect repeated across all 26 therapy areas.
Live berechnet aus 476 anchors
Häufige Fragen
Common causes include manufacturing quality problems, concentration of production at a few sites, active-ingredient supply disruption, sudden demand surges and commercially unattractive margins on older generics.
In many jurisdictions a pharmacist may substitute a therapeutically equivalent generic without prior approval, but switching to a different molecule generally requires prescriber authorisation. Rules vary by country.
Only with medical guidance and after checking your national import rules. Shortages attract counterfeit sellers, so verification standards should be raised, not relaxed, at exactly this moment.
Quellen und weiterführende Literatur
Jede sachliche Aussage oben ist zu einer öffentlichen Primärquelle rückverfolgbar. Wir zitieren Regulierer und Gesundheitsbehörden, keine Händler.
- 1Drug Shortages DatabaseU.S. Food & Drug Administration
- 2Medicines and Healthcare products Regulatory AgencyUK Government
- 3Generic and Hybrid MedicinesEuropean Medicines Agency
- 4MedlinePlus Drug InformationU.S. National Library of Medicine
Wie dieser Artikel entstand
Geschrieben und recherchiert
Health Affordability Editor, Jivan Editorial TeamRedaktionell geprüft
Editorial Review Board — Jivan
Sources checked against Tier-1/Tier-2 references.
Wichtiger medizinischer Hinweis
Ändern Sie Medikament, Dosis oder Hersteller nur nach Rücksprache mit einer approbierten Ärztin oder einem approbierten Arzt. Jivan liefert Bildungs- und Preisinformationen und ersetzt keine Diagnose oder Notfallversorgung.